Evaluation of calcium dobesilate for its anti-cataract potential in experimental animal models

Methods Find Exp Clin Pharmacol. 2010 Apr;32(3):171-9. doi: 10.1358/mf.2010.32.3.1423888.

Abstract

The present study evaluated the protective action of calcium dobesilate (CDO) in various experimental models of cataract. CDO was studied in hydrocortisone-induced cataract in developing chick embryos and selenite-induced cataract in pups. CDO anti-cataract activity was also evaluated after oral and topical application as eye drops in galactose (30%) fed rats. This study was further extended to evaluate the intraocular penetration of a single dose of 1% CDO (50 microL) in rabbits. CDO exhibited significant protection against cataract in experimental models and considerable penetration after single topical application. Anti-cataract activity may be due to its antioxidant as well as aldose reductase inhibitor properties. Further studies are in progress to evaluate its clinical efficacy in diabetic cataract.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Administration, Topical
  • Aldehyde Reductase / antagonists & inhibitors
  • Animals
  • Calcium Dobesilate / administration & dosage
  • Calcium Dobesilate / pharmacology*
  • Cataract / drug therapy*
  • Cataract / physiopathology
  • Chick Embryo
  • Disease Models, Animal
  • Female
  • Galactose / toxicity
  • Hemostatics / administration & dosage
  • Hemostatics / pharmacology*
  • Hydrocortisone / analogs & derivatives
  • Hydrocortisone / toxicity
  • Male
  • Ophthalmic Solutions
  • Oxidative Stress
  • Rabbits
  • Rats
  • Rats, Wistar
  • Sodium Selenite / toxicity

Substances

  • Hemostatics
  • Ophthalmic Solutions
  • Calcium Dobesilate
  • Aldehyde Reductase
  • Sodium Selenite
  • hydrocortisone hemisuccinate
  • Hydrocortisone
  • Galactose